Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of daprodustat versus darbepoetin alfa for anemia in hemodialysis-dependent chronic kidney disease
CTR20261000Phase 3Active
- Sponsor
- Shandong Bainuo Pharmaceutical
- Start
- Jun 2026
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of daprodustat, darbepoetin alfa in anemia of chronic kidney disease, sponsored by Shandong Bainuo Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
daprodustatdarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on CTR20261000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261000.